ClinicalTrials.gg
CompletedNCT04024072Updated Mar 6, 2023Results posted

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

A Phase 3 interventional study of Brinzolamide 1% ophthalmic suspension and Azopt 1% Ophthalmic Suspension in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Padagis LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-06.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
495
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies testing brinzolamide in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. brinzolamide · Glaucoma, Open-Angle.

Enrollment
6th of 28
495 · median 209
Started
2019
the only one that year
Phase 3
10 of 28
none open now
Registered
28th of 28
by date
Lead sponsor
1 of 28
Padagis LLC

Among the 28 studies testing brinzolamide in Glaucoma, Open-Angle, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 10 in phase 3, and was the 28th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 28 studies testing brinzolamide in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →

Where they have run

About brinzolamide

brinzolamide: first FDA approval 1998 (AZOPT), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing brinzolamide in Glaucoma, Open-Angle as a file.
02

Study summary

To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes
  2. Subject requires treatment of both eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate .
  3. Adequate wash-out period prior to baseline of any ocular hypotensive medication.
  4. Baseline (Day 0/hour 0) pressure ≥ 22 mm Hg and ≤ 34 mm Hg in each eye and any asymmetry of pressure between the eyes no greater than 5 mm Hg.
  5. Baseline best corrected visual acuity equivalent to 20/200 or better in each eye

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant, breast feeding, or planning a pregnancy.
  2. Females of who do not agree to utilize an adequate form of
  3. Current, or past history of, severe hepatic or renal impairment
  4. Current, or history within two months prior to baseline of, significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye
  5. Current corneal abnormalities that would prevent accurate readings with the Goldmann applanation tonometer
  6. Functionally significant visual field loss
  7. to brinzolamide or sulfonamide therapy or known to any component of brinzolamide or sulfonamide therapy
  8. Use at any time prior to baseline of an intraocular implant
  9. Use within one week prior to baseline of contact lens
  10. Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, or 2) topical corticosteroid
  11. Use within one month prior to baseline of: 1) systemic corticosteroid or 2) high-dose salicylate therapy
  12. Use within six months prior to baseline of intravitreal or subtenon injection of ophthalmic corticosteroid
  13. Having undergone within six months prior to baseline any other intraocular surgery (e.g., cataract surgery)
  14. Having undergone within twelve months prior to baseline refractive surgery, filtering surgery, or laser surgery for pressure reduction
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
495 participants (actual)

Study arms

  • Experimental
    Perrigo active

    Test product

    Drug: Brinzolamide 1% ophthalmic suspension

  • Active comparator
    Reference active

    Azopt ophthalmic suspension

    Drug: Azopt 1% Ophthalmic Suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Intra-ocular Pressure

    mean change in intra-ocular pressure of both eyes at four time points : at approximately 8:00 a.m. (hour 0; before the morning drop) and approximately 10:00 a.m. (hour 2) on Day 14 (Week 2) and Day 42 (Week 6) visits.

    Time frame: 6 weeks

07

Results

Posted Mar 6, 2023

Participant flow

Participant flow — Overall Study
MilestonePerrigo ActiveReference Active
Started249246
Completed247237
Not completed29

Outcome measures

PrimaryMean Change in Intra-ocular Pressure

mean change in intra-ocular pressure of both eyes at four time points : at approximately 8:00 a.m. (hour 0; before the morning drop) and approximately 10:00 a.m. (hour 2) on Day 14 (Week 2) and Day 42 (Week 6) visits.

Time frame:
6 weeks
Reported as:
Mean · mmHG
Mean Change in Intra-ocular Pressure
mmHGPerrigo ActiveReference Active
8AM Day 14-4.25 ± 2.713-3.80 ± 2.719
10AM Day 14-4.22 ± 2.722-4.00 ± 2.756
8AM Day 42-4.43 ± 2.967-4.20 ± 2.591
10AM Day 42-4.05 ± 2.961-4.06 ± 2.842
Statistical analysis
  • Perrigo Active vs Reference Active · Mean difference (net): -0.46 · 95% CI -0.93 to 0.01
  • Perrigo Active vs Reference Active · Mean difference (net): -0.23 · 95% CI -0.70 to 0.24
  • Perrigo Active vs Reference Active · Mean difference (net): -0.24 · 95% CI -0.74 to 0.27
  • Perrigo Active vs Reference Active · Mean difference (net): -0.00 · 95% CI -0.51 to 0.51

Adverse events

Collected over Day 1 to Day 46. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Perrigo Active0/249 (0%)0/249 (0%)32/249 (12.9%)
Reference Active0/246 (0%)1/246 (0.4%)36/246 (14.6%)
Most frequent serious events
Most frequent serious events
EventPerrigo ActiveReference Active
Upper respiratory tract infectionInfections and infestations—1/246
Most frequent other events
Most frequent other events
EventPerrigo ActiveReference Active
DysgeusiaNervous system disorders23/24921/246
vision blurredEye disorders9/24915/246

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Perrigo ActiveReference ActiveTotal
<=18 years000
Between 18 and 65 years9896194
>=65 years151150301
Age, Continuous
Age, Continuous(years)Perrigo ActiveReference ActiveTotal
Mean65.8 ± 9.8565.6 ± 11.1265.7 ± 10.49
Sex: Female, Male
Sex: Female, Male(Participants)Perrigo ActiveReference ActiveTotal
Female145132277
Male104114218
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Perrigo ActiveReference ActiveTotal
Hispanic or Latino253156
Not Hispanic or Latino223215438
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Perrigo ActiveReference ActiveTotal
American Indian or Alaska Native000
Asian5510
Native Hawaiian or Other Pacific Islander101
Black or African American8184165
White161155316
More than one race123
Unknown or Not Reported000
Iris Color
Iris Color(Participants)Perrigo ActiveReference ActiveTotal
Right eye — Dark158163321
Right eye — Light9183174
Left eye — Dark158162320
Left eye — Light9184175
08

Study locations

1 site
  • James D. Branch Ophthalmology
    Winston-Salem, North Carolina 27101, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Feb 2020, 8 months.

Results were first posted in Mar 2023, 3 years after primary completion.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 8 months is below that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Jul 18, 2019
StartActual
Jun 24, 2019
Primary completionActual
Feb 26, 2020
CompletionActual
Apr 30, 2020
Results first posted
Mar 6, 2023
Last update
Mar 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04024072
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Jul 18, 2019
Start date
Jun 24, 2019
Primary completion
Feb 26, 2020
Completion
Apr 30, 2020
Results posted
Mar 6, 2023
Last update
Mar 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brinzolamide

Start the discussion